Remote patient monitoring using novel technology may make it possible for rheumatologists to choose the “right drug right out of the gate,” according to data presented at the Congress of Clinical Rheumatology East.Jeffrey R. Curtis, MD, of the University of Alabama at Birmingham, noted that a wide array of technological advances, from clinical informatics to drug selection using